Exploring the issues of appropriate dosing in the treatment of acute myocardial infarction: Potential benefits of bolus fibrinolytic agents

American Heart Journal

Volumn 140, Issue 6 SUPPL., 2000, Pages

  Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; RETEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ARTICLE; BRAIN HEMORRHAGE; CLINICAL PROTOCOL; DOSE CALCULATION; DRUG SAFETY; HUMAN; PRIORITY JOURNAL;

EID: 0033674172     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.111605     Document Type: Article

References (31)

1. The costs of adverse drug events in hospitalized patients
2. Relationship between medication errors and adverse drug events
3. Incidence of adverse drug events and potential adverse drug events. Implications for prevention
4. Reducing the rate of medical errors in the United States
5. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial
6. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial
7. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
8. A comparison of reteplase with alteplase for acute myocardial infarction
9. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
10. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction
11. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2
12. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial
13. Rates of serious bleeding requiring transfusion in AMI patients treated with TNK-tPA
14. More rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
15. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator
16. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction
17. Thrombolytic therapy for acute myocardial infarction
18. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial
19. A randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
20. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
21. Lower dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage
22. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-I trial
23. InTIME 2 trial
24. A new regimen for heparin use in acute coronary syndromes
25. Relationship between the presence and duration of chest pain and blood flow at 90 minutes following thrombolytic administration
26. North American vs non-North American streptokinase use in GUSTO-I: Impact of protocol deviation on mortality benefit of TPA
27. Dosing errors and outcomes in patients receiving single bolus compared with bolus + infusion thrombolytic regimens: An InTIME-II study
28. Highlights from the Seventy-second Scientific Sessions of the American Heart Association, November 6-10, 1999
29. Time to treatment and cost of thrombolysis: A multicenter comparison of tPA and rPA
30. Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
31. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial